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Abstract
Genome-wide association studies have identified 20 genomic regions associated with risk of epithelial ovarian cancer (EOC), 
but many additional risk variants may exist. Here, we evaluated associations between common genetic variants [single 
nucleotide polymorphisms (SNPs) and indels] in DNA repair genes and EOC risk. We genotyped 2896 common variants at 
143 gene loci in DNA samples from 15 397 patients with invasive EOC and controls. We found evidence of associations with 
EOC risk for variants at FANCA, EXO1, E2F4, E2F2, CREB5 and CHEK2 genes (P ≤ 0.001). The strongest risk association was for 
CHEK2 SNP rs17507066 with serous EOC (P = 4.74 x 10–7). Additional genotyping and imputation of genotypes from the 1000 
genomes project identified a slightly more significant association for CHEK2 SNP rs6005807 (r2 with rs17507066 = 0.84, odds 
ratio (OR) 1.17, 95% CI 1.11–1.24, P = 1.1 × 10−7). We identified 293 variants in the region with likelihood ratios of less than 
1:100 for representing the causal variant. Functional annotation identified 25 candidate SNPs that alter transcription factor 
binding sites within regulatory elements active in EOC precursor tissues. In The Cancer Genome Atlas dataset, CHEK2 gene 
expression was significantly higher in primary EOCs compared to normal fallopian tube tissues (P = 3.72 × 10−8). We also 
identified an association between genotypes of the candidate causal SNP rs12166475 (r2 = 0.99 with rs6005807) and CHEK2 
expression (P = 2.70 × 10-8). These data suggest that common variants at 22q12.1 are associated with risk of serous EOC and 
CHEK2 as a plausible target susceptibility gene.
Introduction
Epithelial ovarian cancer (EOC) is the leading cause of death 
from cancers of the female reproductive tract (1). Established 
protective risk factors for the disease include pregnancy, oral 
contraceptives and breast-feeding, factors which reduce the 
number of lifetime ovulatory cycles. The biological mechanisms 
underlying these associations are not well understood but may 
involve proliferation, inflammation, oxidative stress, mutation 
and DNA repair in the ovarian and/or fallopian tube epithelia 
(2–4). Several studies have highlighted the critical role in ovarian 
tumorigenesis of maintaining genomic integrity, either through 
DNA repair or apoptotic pathways (5).
The importance of highly penetrant genetic risk factors for 
EOC has become evident from studies of familial clustering 
of breast and ovarian cancers, largely caused by mutations in 
the BRCA1 and BRCA2 (6–8). Several additional susceptibility 
genes exist that confer more moderate risks of EOC (e.g. MSH6, 
MSH2, MLH1, RAD51C, RAD51D and BRIP1 (9–12)). Finally, several 
common genetic variants conferring relatively mild risks of 
EOC have been identified in genome-wide association studies 
(GWAS) (13–21).
Whereas GWAS are highly successful at identifying com-
mon variant susceptibility alleles for multiple complex traits 
and diseases using case–control study designs, only a frac-
tion of the total number of risk variants for any one disease 
have been identified to date. For example, Michailidou et al. (22) 
estimated that many common risk variants for breast cancer 
await discovery; and the same is likely true of other cancers. 
One approach to identify additional susceptibility alleles is to 
integrate knowledge of disease biology with germline genetic 
datasets (i.e. candidate gene or pathway studies). This approach 
has recently been successful in identifying the 5p15 (TERT-
CLPTM1L) susceptibility locus for breast, prostate and ovarian 
cancers (18).
CHEK2 is a putative tumor suppressor gene that encodes a 
protein kinase activated in response to DNA damage and has 
also been shown to interact with and phosphorylate BRCA1, 
promoting cellular survival after DNA damage (23). A deletion 
variant in CHEK2 (CHEK2*1100delC) is associated with a 2–3-
fold increased risk of breast cancer but is not associated with 
ovarian cancer risk (24). However, other CHEK2 coding variants 
may confer susceptibility to ovarian cancer, and in one study, 
five CHEK2 missense variants were identified in an analysis of 
360 EOC cases, two of which were predicted to be damaging in 
functional assays (25). Common low penetrance variants may 
also exist in and around the CHEK2 gene. We previously evalu-
ated associations for germline genetic variants spanning 53 
DNA damage response and repair genes and risk of invasive 
serous EOC in 364 EOC cases and 761 controls from the North 
Carolina Ovarian Cancer Study (NCOCS), and identified border-
line evidence of an association for two variants (rs5762746 and 
rs6005835) in CHEK2 (26).
In this study, we expanded the examination of risks associ-
ated with DNA repair genes by genotyping 2896 single nucleo-
tide polymorphisms (SNPs) and indel variants spanning 143 
gene loci in DNA samples of 15 397 EOC cases and 30 816 con-
trols as part of the Collaborative Oncological Gene-environment 
Study (COGS). Imputation of additional SNPs in COGS further 
defined risk associations at the CHEK2 locus. Finally, we inte-
grated germline genetic data with functional annotation of the 
region to identify the most likely disease-causing susceptibility 
variants and target genes at this locus.
Materials and methods
Genetic association analyses
Study datasets
Genetic association analyses were carried out using data from several 
Ovarian Cancer Association Consortium (OCAC) genotyping projects. 
Study subjects were of European ancestry (determined using principal 
components analysis of genotype data): 2162 cases and 2564 controls from 
a GWAS from North America (‘US GWAS’), 1763 cases and 6118 controls 
from a UK-based GWAS (‘UK GWAS’) and 441 cases and 442 controls from 
a second GWAS from North America (‘Mayo GWAS’) (13–19,21). In total, 11 
030 cases and 21 693 controls from 41 OCAC studies were genotyped using 
the iCOGS array (‘OCAC-iCOGS’ stage 1 data). The USA and UK GWAS were 
comprised of several independent case–control studies, and samples from 
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some of these studies were also subsequently genotyped using the iCOGS 
array. Combined, these studies comprised 15 396 independent cases and 
30 817 controls. All duplicates were removed. Further details of the com-
ponent studies are in Supplementary Table 1, available at Carcinogenesis 
Online. Details of genotyping platform are shown in Supplementary 
Table 2, available at Carcinogenesis Online.
Variant selection
To select genes, we expanded upon the 53 genes included in our earlier 
investigation (26) using the gene sets described in Wood et  al. (27) plus 
literature and gene ontology database searches, ultimately identifying 143 
genes whose functions relate to DNA damage recognition and repair pro-
cesses for inclusion in this study. For each gene, we identified all SNPs 
within genome windows ranging from 10 kb upstream of the transcription 
start sites to 10 kb downstream of the transcription end sites of the 143 
genes DNA repair genes. These variants were included in the US ovarian 
cancer GWAS database of SNPs imputed by the MACH software package 
against Hapmap Phase II genotypes (Release 22, NCBI build 36) for 60 CEU 
founders. We used these data to conduct a preliminary association analy-
sis and to identify tag sets for each region, tagging polymorphisms with 
minor allele frequencies (MAF) of at least 0.025 to an r2 of 0.80 or above. 
We ranked the genes on basis of the most significant variants within each 
gene. We tagged SNPs at TP53, CHEK2 and the top five ranked genes to an 
r2 of 0.975, the genes ranked 6 through 124 to an r2 of 0.90 and the 20 low-
est ranked genes to an r2 of 0.80. We then chose the SNP with the highest 
Illumina design score as the tag in each r2 bin, choosing the most highly 
significant SNP when there were ties. This yielded 3651 variants that were 
included on the COGS Illumina custom iSelect chip (iCOGS). After qual-
ity control analysis, 3252 variants passed QC of which 53 had MAF < 0.02 
(Supplementary Table 3 and Figure 1, available at Carcinogenesis Online).
Imputation
OCAC-iCOGS samples and each of the GWAS sets were imputed separately. 
Variants were imputed from the 1000 Genomes Project data using the v3 
April 2012 release as the reference panel. We used a two-step procedure, 
which involved prephasing in the first step (using the SHAPEIT software 
and imputation, of the phased data in the second step using the IMPUTE 
version 2 software (28). To perform the imputation, we divided the data 
into segments of ~5 Mb and excluded variants from the association analy-
sis if their imputation accuracy was r2 < 0.25 or their MAF was <0.005. The 
number of successfully imputed SNPs by MAF is shown in Supplementary 
Table 4, available at Carcinogenesis Online.
Data analysis
Analyses were restricted to women of European intercontinental ances-
try. We performed principal components analysis using a set of ~37 000 
unlinked markers to control for population substructure; an in-house 
program was utilized (available at http://ccge.medschl.cam.ac.uk/soft-
ware/). Unconditional logistic regression treating the number of alternate 
alleles carried as an ordinal variable (log-additive, codominant model) 
was used to evaluate the association between each variant and EOC risk. 
A  likelihood ratio statistic was used to examine significance of associa-
tion, and per-allele log odds ratios (OR) and 95% confidence interval (CI) 
were estimated. The logistic regression model was adjusted for study and 
population substructure by including study-specific indicators and a vari-
able number of eigenvalues from the principal components analyses. The 
number of principal components was chosen based on the position of the 
inflexion of the principal components screen plot. Two principal compo-
nents were included in the analysis of the UK and US GWAS data sets, 
one was used for the Mayo GWAS and five were used for the COGS-OCAC 
dataset. Results from the three GWAS and COGS were combined using 
fixed-effects, inverse variance weighted meta-analysis.
Functional analyses
Public databases
To perform functional annotation of 293 candidate variants and expres-
sion quantitative trait locus (eQTL) analysis at the CHEK2 locus, we mined 
the following databases: ENCODE (http://genome.ucsc.edu); Haploreg 
(http://www.broadinstitute.org/mammals/haploreg/haploreg.php); and 
The Blood eQTL Browser (http://genenetwork.nl/bloodeqtlbrowser/) (29).
Profiling of epigenetic marks in ovarian cancer and ovarian 
cancer precursor cells
FAIREseq and ChIPseq profiles were generated for two immortalized nor-
mal ovarian surface epithelial cell lines (IOE4 and IOE11, generated in-
house) and two fallopian secretory epithelial cell lines (FT33 and FT246, 
from Dr R Drapkin) as described previously (30). The CaOV3 and UWB1.289 
(31) ovarian cancer cell lines (from CRUK and ATCC, respectively) were 
also profiled. Prior to performing ChIPseq/FAIREseq, cell lines were 
authenticated using the Promega PowerPlex16HS Assay (performed at the 
University of Arizona Genetic Core), and mycoplasma-specific PCR was 
performed to ensure cell lines were not contaminated with mycoplasma 
infections. ChIPseq was performed using antibodies that recognized 
histone 3 lysine 27 acetylation (H3K27ac) and histone 3 lysine 4 mono-
methylation (H3K4me) (Abcam). Identification of variants predicted sig-
nificantly to alter transcription factor motifs was performed as described 
by Hazelett et al. (32).
Collection of normal epithelial samples
Early passage primary normal ovarian surface epithelial cells and fal-
lopian tube secretory epithelial cells were obtained from disease-free 
ovaries and fallopian tubes collected during gynecological surgical pro-
cedures taking place at the University of Southern California, Los Angeles 
(the Gynecological Tissue and Fluid Repository), University College 
Hospital, London and Oregon Health and Science University. All samples 
were collected with informed patient consent. Methods for the collection 
have been described previously (33,34). RNA extraction was performed 
from cells at 80% confluence using standard protocols. Cell lines were con-
firmed to be free of mycoplasma, but were not authenticated as they were 
novel cell lines used at an early passage.
eQTL data analysis
For each sample, 500 ng RNA were reverse transcribed using the Superscript 
III kit (Life Technologies). TaqMan® was used to quantify CHEK2 gene 
expression using a TaqMan® gene expression probe (Hs00200485_m1, Life 
Technologies). Four control genes were also included: ACTB, Hs00357333_
g1; GAPDH, Hs02758991_g1; HMBS, Hs00609293_g1; and HPRT1 Hs0280069_
m1 (all Life Technologies). Relative expression levels were calculated using 
the ΔΔCt method. Correlations between genotype and gene expression 
were calculated in R using a Jonckheere–Terpstra trend test (for three 
groups) or the Wilcoxon rank sum statistic (for 2 groups).
eQTL analysis using TCGA data
Publicly available microarray and germline genotyping data for high-grade 
serous EOCs was downloaded from TCGA (Lawrenson et  al, Nat Comm, 
accepted). For each case, germline genotyping data were used to deter-
mine ancestry using principal components through EIGENSTRAT software 
(HapMap profiles were used as a control set). Only cases with complete 
Northern or Western European ancestry were included. Cis-eQTL analyses 
were performed for all genes in a 1MB region spanning the top variant, 
using a method we have described previously (35). Associations between 
risk variant genotypes and mRNA expression for 339 cases were evaluated 
using a linear regression model adjusting for the effects of copy number 
and methylation. The Benjamini–Hochberg method was used to adjust for 
Abbreviations 
COGS Collaborative Oncological Gene-environment  
 Study 
EOC epithelial ovarian cancer
eQTL expression quantitative trait locus
GWAS genome-wide association studies
HGSOC high-grade serous ovarian cancer 
MAF minor allele frequency
SNP single nucleotide polymorphism 
TFBS transcription factor binding site
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multiple testing. A significant association was defined by a false discovery 
rate of less than 0.1.
Results
Genetic association analyses of DNA repair gene loci
For 143 DNA repair genes, we identified 2896 tagging SNPs (minor 
allele frequencies (MAFs) > 2%) that lie within 10 kb upstream 
and downstream of the transcription start and end sites of each 
gene; these variants were genotyped as part of iCOGS. Of these, 
2 621 were successfully genotyped in 46 213 subjects from 43 
studies. This sample included 15 397 women diagnosed with 
invasive EOC, of whom 9608 cases had serous ovarian cancer, 
and 30 816 controls. Details of the study populations, genotyp-
ing platforms used for each data set and quality control analysis 
are given in Supplementary Tables 1–3 and Figure 1, available at 
Carcinogenesis Online.
Supplementary Table  5, available at Carcinogenesis Online, 
lists the DNA repair genes evaluated in this study, including the 
number of tag SNPs at each locus, and the significance of asso-
ciation (P value) with serous ovarian cancer for the most signifi-
cant risk-associated variant for each gene. The data for all SNPs 
and genes are illustrated in Figure 1A. SNPs at 6 different genes 
were associated with serous ovarian cancer risk at a P value 
threshold of 0.001: FANCA on chromosome 16q24.3 (P = 0.001); 
EXO1 on chromosome 1q43 (P = 0.0005); E2F4 on chromosome 
16q22.1 (P = 0.0005); E2F2 on chromosome 1p36.12 (P = 0.0004); 
CREB5 on chromosome 7p15.1 (P = 0.0002) and CHEK2 on chro-
mosome 22q12.1 (P = 4.7 × 10−7).
The genomic inflation factor λ for the combined meta-analy-
sis analysis was 1.15 (adjusted value to 1000 cases and controls 
λ1000 = 1.01). This may be due to cryptic population structure not 
accounted for by adjusting for principal components. However, 
there was no residual inflation observed for association with 
clear cell and mucinous ovarian cancers (λ  =  1.01 and 0.93, 
respectively) and minimal inflation for the larger set of SNPs on 
the iCOGS array that had not been selected as candidates for 
EOC susceptibility (λ = 1.07, λ1000 = 1.004).
Genetic association analyses of the CHEK2 
gene locus
CHEK2 showed the strongest evidence of association with 
serous ovarian cancer risk, for SNP rs17507066 (odds ratio (OR) 
0.86; 95% confidence interval (95% CI) 0.81–0.91). Because CHEK2 
is a known moderately penetrant susceptibility gene for breast 
cancer, additional common variants in the region spanning 
this gene had been included on the iCOGS array at providing 
a greater density within the region than for other DNA repair 
genes (16). Genotype data were available for a further 176 vari-
ants in this sample set in addition to the 24 tagging SNPs origi-
nally evaluated. Further genotyping identified rs9625477 with 
a marginally more significant association with serous ovarian 
cancer risk (P = 2.4 × 10−7). The data for the association analysis of 
all 200 genotyped variants in the region in serous ovarian cancer 
are given in Supplementary Table 6, available at Carcinogenesis 
Online.
We further evaluated this region after imputing genotypes for 
variants identified through the 1000 Genomes Project for all par-
ticipants of European ancestry (Supplementary Table 7, available 
at Carcinogenesis Online). After excluding poorly imputed SNPs, a 
total of 4785 SNPs with an imputation r2 > 0.3 and an estimated 
MAF >0.02% spanning a 2 Mb region on 22q12.1 (nucleotide posi-
tion 28 000 000 to 30 000 000) were analyzed for their associations 
with high-grade serous ovarian cancer (HGSOC) risk. This analy-
sis identified multiple additional variants highly correlated with 
rs9625477, several of which were more significantly associated 
with disease risk. All imputed risk-associated variants with 
P value less than threshold 10−6 are given in Supplementary 
Table 7, available at Carcinogenesis Online. The most significant 
risk association was for SNP rs6005807 (OR 1.17, 95%CI 1.11–1.24, 
P = 1.1 − 10−7), which is correlated with rs9625477 (r2 = 0.99). Risk 
associations for genotyped and imputed SNPs in HGSOC across 
the regions are illustrated in Figure 1B.
We stratified risk associations by histological subtype. The 
most significant SNP for serous ovarian cancer (rs6005807) was 
more weakly associated with all invasive subtypes of EOC com-
bined (P = 2.9 × 10−6) and showed no evidence of association for clear 
cell (P = 0.65), endometrioid (P = 0.55) or mucinous (P = 0.33) sub-
types. However, other variants in the region (all imputed) showed 
subtype-specific associations: rs78371015 (r2 0.97 with rs6005807) 
was the strongest risk allele for the clear cell subtype (P = 0.0002); 
rs34051361 (r2  =  0.56 with rs6005807) was associated with the 
endometrioid subtype (P = 0.0001); and the variant 22:29126347:D 
(r2 = 0.92 with rs6005807) was associated with the mucinous sub-
type (P = 0.0001). Summary results are given in Table 1.
Functional annotation of risk-associated variants
Two hundred and ninety-three variants (genotyped or imputed), 
representing the most likely candidate causal variants at the locus, 
had likelihood ratios greater than 1:100 compared with the most 
significant SNP in serous ovarian cancer. The majority of candi-
date causal variants were SNPs (267/293, 91.1%); the remaining 
26/293 (8.9%) were indel polymorphisms. We annotated these SNPs 
with respect to protein coding genes, predicted functional motifs 
and regulatory elements cataloged in ENCODE and Haploreg. Two 
SNPs were located in protein coding regions of the TTC28 gene; 
both were synonymous and therefore unlikely to be of functional 
importance. The remaining variants were located in non-coding 
DNA regions: 274 (93.5%) were located within introns of the TTC28 
gene, and 12 (4.1%) were located within introns of the CHEK2 gene 
(Figure 2). Fifty-four SNPs (18.4%) coincide with enhancer or pro-
moter elements annotated in ENCODE, 51 SNPs (17.4%) are located 
in DNase hypersensitivity domains and 241 SNPs (82.3%) are pre-
dicted to alter transcription factor binding motifs in Haploreg 
(Supplementary Table  8, available at Carcinogenesis Online). To 
define further the overlaps between risk variants and putative 
functional features, we identified those variants predicted signifi-
cantly to alter transcription factor binding sites (TFBSs) identified 
using data from FactorBook (32,36). We only considered TFBS vari-
ants that lie within regulatory DNA regions active in EOC precursor 
tissues. Active regulatory elements in normal ovarian and fallopian 
epithelial cells were profiled using formaldehyde assisted isolation 
of regulatory element sequencing (FAIRE-seq) to identify regions of 
open chromatin, and chromatin immunoprecipitation sequencing 
(ChIP-seq) for histone modification marks H3K4me1 and H3K27ac 
(37). We identified 25 instances where candidate SNPs altered TFBSs 
within active regulatory sequences (Supplementary Table 9, availa-
ble at Carcinogenesis Online), suggesting that these SNPs may be the 
most likely candidate causal variants at this locus. HOCOMOCO 
(38) was also used to identify transcription factors that may bind 
to the risk associated SNPs. We found that rs12166475 is predicted 
to affect binding of WT1, and that rs9620817 and rs16986509 are 
predicted to alter TFBSs for BRCA1; both transcription factors are 
known to be important in risk of development of HGSOC. These 
data are summarized in Supplementary Table  10, available at 
Carcinogenesis Online and Figure 2C.
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Functional analyses of candidate genes
We used somatic data to evaluate the role in EOC development 
of all protein-coding genes within a 1Mb region spanning the 
most significant risk-associated SNP (rs6005807) to identify 
the most likely susceptibility target gene. Six genes lie in the 
region: rs6005807 is located in an intron of TTC28 (tetratri-
copeptide repeat domain 28); 5′ prime of TTC28 are CHEK2, 
HSCB (HscB mitochondrial iron-sulfur cluster co-chaperon), 
CCDC117 (coiled-coil domain containing 117), XBP1 (X-box 
binding protein 1), and ZNRF3 (zinc and ring finger 3). We eval-
uated somatic genetic alterations in primary ovarian tumors 
for these six genes using The Cancer Genome Atlas (TCGA) 
data and other public databases (summarized in Table 2).
These analyses revealed that 11% of high-grade serous 
ovarian cancer (HGSOC) cases showed copy number gain or 
amplification in the region spanning the six candidate genes, 
whereas homozygous deletions were rare (<1% cases). We identi-
fied a somatic coding sequence mutation in both the CHEK2 and 
ZNRF3 genes out of 316 sequenced HGSOC cases. The mutation 
in CHEK2 is a missense (R346H) predicted to be of ‘high impact’ 
(mutationassesor.org). The ZNRF3 mutation is also missense 
(P805H), but predicted to have little functional impact. Using 
another database of somatic mutation frequencies (COSMIC), 
which includes data for over 8000 tumors, we observed that 
CHEK2 was the most frequently mutated (in 2.5% of cases) of all 
the genes in the region (42).
We examined differences in gene expression between nor-
mal and cancer tissues (Figure 2D). CHEK2 gene expression was 
significantly higher in HGSOCs (n  =  489) compared to normal 
fallopian tube tissues (P = 3.7 × 10−8). TTC28 was the only other 
Figure 1. (A) Manhattan plot illustrating associations between 2621 SNPs spanning 143 DNA repair genes and risk of high-grade serous ovarian cancer. SNPs colored 
red are the top ranked risk associations at the CHEK2 gene locus. (B) Regional association plot for the 22q12.1 locus showing the distribution of genotyped (black dots) 
and imputed (red dots) SNPs and the genetic architecture with respect to the 19 genes in the region.
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gene in the region that was differentially expressed in ovarian 
cancers with lower expression in tumors compared to normal 
control tissues (P  =  0.01). We also evaluated the expression of 
these genes in a stepwise model of early-stage ovarian epithelial 
cell transformation driven by overexpression of the CMYC gene 
and mutant KRAS (Figure 2E) (43). In this model, CHEK2, HSBC, 
Table 1. Risk associations for the top SNPs at the CHEK2 locus, by histological subtype
Top SNP EOC subtype Position Number of cases SNP location (nearest gene) r2 COGS Odds ratio 95% CI P value
rs6005807 Serous 28934313 9608 Intronic (TTC28) 1 1.17 1.11–1.24 1.1 × 10−07
All invasive 15 397 1.12 1.07–1.18 2.9 × 10−06
Clear cell 1172 1.04 0.89–1.20 0.65
Endometrioid 2385 1.03 0.93–1.15 0.55
Mucinous 1112 1.07 0.92–1.24 0.33
rs5752754 All invasive 28925542 15 397 Intronic (TTC28) 0.94 1.11 1.06–1.16 2.4 × 10−06
rs78371015 Clear cell 29245611 1172 Intergenic (ZNRF3) 0.97 1.40 1.17–1.67 0.0002
rs34051361 Endometrioid 29582557 2385 Intergenic (KREMEN1) 0.56 1.57 1.24–1.98 0.0001
chr22:29126347:D Mucinous 29126347 1112 Intergenic (ZNRF3) 0.92 1.56 1.25–1.98 0.0001
Figure 2. Functional annotation of candidate genes and SNPs at the 22q12 locus. We analysed the genes and ovarian cancer risk associated variants in a 1MB region spanning 
the top ranked risk SNP at this locus: (A) The location of all protein coding genes in the 1 MB region spanning the ranked risk SNP, and the 298 SNPs in the region with a 100:1 
likelihood of being causal; (B) Illustration of the regulatory elements identified by RNAseq and ChIPseq analysis (H3K4me1, H3K4me3 and H3K27ac) catalogued by ENCODE, 
illustrates the extent of overlap between candidate SNPs and epigenetic marks; (C) The three most significant candidate SNPs identified through a combination of functional 
annotation, eQTL analyses and transcription factor binding site prediction. Position weight matrices for each factor are shown with SNP position indicated. Ref, reference 
allele; Alt, alternative allele; PCT; percent of maximum position weight matrix score for each allele; (D) Gene expression in 489 HGSOCs and 8 normal fallopian tube tissue 
specimens performed by TCGA indicates CHEK2 is the most significantly differentially expressed gene in the region; (E) mRNA expression of each gene in an in vitro early stage 
transformation model of ovarian cancer. Expression in CMYC and KRAS transformed cells compared to untransformed immortalized ovarian epithelial (IOE) cells (*P < 0.05). 
K.Lawrenson et al. | 1349
Ta
b
le
 2
. 
C
an
d
id
at
e 
ge
n
e 
an
al
ys
es
 a
n
d
 e
Q
T
L 
an
al
ys
es
G
en
e
Fu
n
ct
io
n
a
T
C
G
A
 g
en
e 
ex
p
re
ss
io
n
 
tu
m
or
 (n
 =
 4
89
) v
er
su
s 
n
or
m
al
 F
T
 (n
 =
 8
)
T
C
G
A
 s
om
at
ic
 m
u
ta
ti
on
 
ra
te
 H
G
SO
C
 N
 =
 3
16
 (%
)
C
O
SM
IC
 s
om
at
ic
  
m
u
ta
ti
on
s
N
 u
n
iq
u
e 
m
u
ta
ti
on
s/
N
 
u
n
iq
u
e 
sa
m
p
le
s 
te
st
ed
 (%
)
Ex
p
re
ss
io
n
 q
u
an
ti
ta
ti
ve
 t
ra
it
 lo
cu
s 
(e
Q
T
L)
 a
n
al
ys
is
Ly
m
p
h
oc
yt
e 
eQ
T
L 
an
al
ys
es
T
C
G
A
 e
Q
T
L 
an
al
ys
es
N
or
m
al
 O
SE
C
 
(n
 =
 6
5)
rs
17
50
70
6 
P 
va
lu
e
P 
va
lu
e
M
ea
n
 
N
or
m
al
 
FT
M
ea
n
 
H
G
SO
C
SN
P
P 
va
lu
e
FD
R
SN
P
P 
va
lu
e
FD
R
T
T
C
28
In
vo
lv
ed
 in
 m
it
os
is
 a
n
d
 c
y-
to
ki
n
es
is
 (3
9)
0.
01
0
0.
34
7
0.
00
1
0.
0
67
/8
20
4 
(0
.8
%
)
N
S
N
S
N
S
N
/A
N
/A
N
/A
N
D
C
H
EK
2
In
vo
lv
ed
 in
 D
N
A
 d
am
ag
e 
re
sp
on
se
3.
7 
×
 1
0−
8
−
1.
29
0.
01
1
0.
3
24
9/
98
30
 (2
.5
%
)
rs
12
16
64
75
b
2.
70
 ×
 1
0−
8
0
rs
60
05
79
0
0.
01
8
1.
0
0.
18
4
H
SC
B
In
vo
lv
ed
 in
 ir
on
-s
u
lf
u
r 
cl
u
st
er
 
bi
og
en
es
is
 (4
0)
0.
36
8
0.
06
5
−
0.
02
0
0.
0
16
/8
53
3 
(0
.2
%
)
rs
96
20
81
7
1.
21
 ×
 1
0−
6
0
N
/A
N
/A
N
/A
N
D
C
C
D
C
11
7
N
ot
 c
h
ar
ac
te
ri
ze
d
0.
09
8
−
0.
15
1
−
0.
00
5
0.
0
25
/8
32
6 
(0
.3
%
)
rs
16
98
65
09
1.
39
 ×
 1
0−
6
0
N
/A
N
/A
N
/A
N
D
X
B
P1
Tr
an
sc
ri
p
ti
on
 f
ac
to
r,
 in
vo
lv
ed
 
in
 t
h
e 
im
m
u
n
e 
sy
st
em
0.
13
0
0.
26
8
−
0.
01
5
0.
0
21
/8
20
4 
(0
.3
%
)
rs
12
16
57
15
1.
16
 ×
 1
0−
12
7
0
rs
71
41
91
0.
04
5
1.
0
N
D
Z
N
R
F3
U
bi
q
u
it
in
 li
ga
se
, i
n
vo
lv
ed
 in
 
W
n
t 
si
gn
al
in
g 
(4
1)
0.
97
5
0.
00
6
0.
00
4
0.
3
67
/8
30
5 
(0
.8
%
)
N
S
N
S
N
S
N
/A
N
/A
N
/A
N
D
N
S,
 n
o 
si
gn
ifi
ca
n
t 
eQ
T
Ls
 d
et
ec
te
d
; N
D
, n
ot
 d
on
e;
 O
SE
C
, o
va
ri
an
 s
u
rf
ac
e 
ep
it
h
el
ia
l c
el
l; 
N
/A
, n
ot
 a
va
il
ab
le
, i
n
 T
C
G
A
 le
ve
l 3
 d
at
a 
th
er
e 
w
er
e 
n
o 
d
at
a 
av
ai
la
bl
e 
fo
r 
H
SC
B
, C
C
D
C
11
7 
an
d
 Z
N
R
F3
.
a G
en
e 
fu
n
ct
io
n
s 
w
er
e 
id
en
ti
fi
ed
 u
si
n
g 
th
e 
N
C
B
I ‘
G
en
e’
 p
ag
es
 u
n
le
ss
 a
lt
er
n
at
iv
e 
re
fe
re
n
ce
s 
ar
e 
p
ro
vi
d
ed
. B
lo
od
 e
Q
T
L 
an
al
ys
es
 w
er
e 
p
er
fo
rm
ed
 u
si
n
g 
d
at
a 
fr
om
 R
ef
 (2
9)
, t
h
e 
to
p
 d
is
ea
se
-a
ss
oc
ia
te
d
 e
Q
T
L 
SN
P 
is
 s
h
ow
n
 f
or
 e
ac
h
 g
en
e.
 
Fo
r 
C
H
EK
2,
 H
SC
B
, C
C
D
C
11
7 
an
d
 X
B
P1
, t
h
e 
to
p
 e
Q
T
L 
SN
P 
w
as
 a
ls
o 
d
is
ea
se
 a
ss
oc
ia
te
d
. b
M
in
or
 a
ll
el
es
 w
er
e 
as
so
ci
at
ed
 w
it
h
 in
cr
ea
se
d
 e
xp
re
ss
io
n
 o
f 
C
H
EK
2,
 H
SC
B,
 C
C
D
C
11
7 
an
d
 X
B
P1
.
1350 | Carcinogenesis, 2015, Vol. 36, No. 11
CCDC117, XBP1 and ZNFR3 all showed significantly increased 
expression in ovarian epithelial cells (P < 0.05) that had under-
gone early stage neoplastic transformation, suggesting that 
the upregulation of these genes may be an early event in EOC 
development.
eQTL analyses
We used eQTL analysis to evaluate associations between risk 
genotypes and the levels of mRNA expression for candidate 
genes in the region (29). We looked for cis-eQTL associations 
in both normal and tumor tissues. We did not detect an eQTL 
for CHEK2 in normal ovarian/fallopian epithelial cultures. In 
peripheral blood samples (N > 5300) we observed a particularly 
strong association between rs12165715 and XBP1 expression 
(P  =  1.16 × 10−127) (29). We also detected associations between 
rs12166475 and CHEK2 expression (P = 2.70 × 10−8), rs9620817 and 
HSCB expression (P  = 1.21 × 10−6), and rs16986509 and CCDC117 
expression (P = 1.29 × 10−6). The variant most significantly associ-
ated with ovarian cancer risk at this locus (rs6005807) showed 
significant eQTL associations for CHEK2 (P = 9.22 × 10−6) and HSCB 
(P = 1.85 × 10−5). Importantly, for CHEK2, HSCB, CCDC117 and XBP1 
the most significant eQTL SNPs were also disease associated. 
These data are summarized in Table 2. Three of the top 25 candi-
date variants from in silico functional annotation were amongst 
the most significant eQTL associations: rs12166475, associated 
with expression of CHEK2 coincides with a TFBS for EGR1, a 
transcription factor previously implicated in EOC development; 
rs9620817, associated with HSCB expression, is predicted to 
alter CEBPB and ETS1 motifs; and rs16986509 associated with 
CCDC117 expression is predicted to alter TFBSs for TAL1 and UA2 
(Figure 2C).
Finally, we evaluated eQTL associations for all six protein-
coding genes in the region in 339 primary HGSOC tissues using 
publicly available data from TCGA. Variations in gene expression 
were adjusted for changes in DNA copy number and methyla-
tion variation in each tumor. We observed no significant asso-
ciations between rs6005807 and CHEK2, TTC28 or XBP1 at a P 
value threshold of 0.05, and false discovery rate threshold of 0.1. 
Details of the eQTL analyses are provided in Table 2.
Discussion
DNA repair mechanisms are important in the initiation and 
development of EOC and the current study represents the most 
comprehensive analysis of common genetic variation at DNA 
repair genes and EOC risk to date. We evaluated 2621 candi-
date variants spanning 143 gene regions at several different 
DNA repair pathways and found strong evidence of risk asso-
ciations for SNPs at the CHEK2 gene locus that were just below 
the threshold for genome-wide significance. This is consistent 
with a smaller previous study in which we showed borderline 
evidence of risk associations for SNPs spanning this locus (26). 
Even though we did not find strong statistical evidence of risk 
associations for SNPs at other DNA repair gene loci, we cannot 
rule out that germline genetic variation at these genes is associ-
ated with EOC risk. We only performed detailed genotyping and 
imputation analysis at the CHEK2 locus because of the strength 
of its association from our initial screen, but additional analy-
ses of the other gene loci in the future may identify other asso-
ciations. COGS represents the largest genetic association study 
reported for EOC, but is still substantially smaller in sample size 
compared to GWAS for more common diseases such as breast 
cancer and coronary artery disease (22,44,45). Sample size has 
a substantial impact on the ability to identify risk associations, 
which partly explains why more common diseases have identi-
fied the most risk associations using GWAS. Disease heterogene-
ity may also have restricted our ability to identify risk variants 
for EOC as some ovarian cancer risk loci are subtype-specific 
(16,19). It is likely that common variants in various DNA repair 
genes confer susceptibility to subtype-specific EOC as observed 
for more highly-penetrant genes. Finally, rarer variants (MAF < 
0.02) in these genes may confer susceptibility to EOC, but we 
did not have adequate power to detect such rarer associations 
in this study.
The genetic data suggest that variants at the CHEK2 locus are 
associated with risk of invasive EOC, but that the association for 
the top ranked SNP (rs6005807) is stronger with serous histology. 
We found no evidence that rs6005807 was associated with other 
EOC histologies but different imputed variants within the region 
showed evidence of association with clear cell, endometrioid 
and mucinous EOC at P values of 0.0002. Because these three 
EOC subtypes are less common than serous EOC, the weakness 
of these associations may simply reflect the smaller sample 
sizes available for their genotyping. One caveat to the associa-
tion analyses lies in the minor residual inflation observed in the 
test statistics. This may be due to population structure but given 
that this inflation was greater than for other sets of SNPs this 
seems an unlikely explanation. An alternative explanation is 
an overall burden of weak susceptibility signals within this set 
of SNPs.
The most significant associations were identified using 
imputed genotypes, based on an estimated imputation r2 that 
indicates a very high correlation between imputed genotypes 
and actual genotypes. It is therefore unlikely that there are 
other common variants within the region that may represent 
more highly associated SNPs than those already identified, and 
so these alleles represent the candidate causal variants for this 
locus. We identified 293 candidate causal polymorphisms that 
are virtually indistinguishable from each other with respect to 
their risk associations and any one (or even several) could be the 
causal SNP(s) influencing expression of the target susceptibility 
gene. Only two of the variants were in protein-coding regions 
and both were synonymous changes, suggesting that the causal 
SNP(s) likely reside in non-coding DNA. As such we neither 
know the functional basis for the genetic susceptibility, nor the 
target susceptibility gene(s). Our in silico analysis of these vari-
ants with respect to non-coding regulatory biofeatures profiled 
in multiple different cell lines by ENCODE, and in EOC precur-
sor tissues, identified 25 risk SNPs that intersect with annotated 
functional elements. While this represents a relatively small 
number of candidate causal polymorphisms and functional 
targets at this locus, several other candidate causal SNPs may 
exist. None of the cell lines we evaluated have been comprehen-
sively analysed for the full catalogue of non-coding regulatory 
elements and is possible that additional variants overlap regula-
tory marks that were not profiled; for example CTCF repressor 
marks and non-coding RNAs.
We identified three risk SNPs located within regulatory ele-
ments active in ovarian cells. These SNPs were also the most 
significant SNPs from eQTL analysis in the region: rs12166475 
associated with CHEK2; rs9620187 associated with HSCB; and 
rs16986509 associated with CCDC117. In each case the minor 
allele was associated with increased gene expression; conse-
quently higher CHEK2, HSCB and CCDC117 expression was asso-
ciated with reduced cancer risk, whereas higher XBP1 expression 
was associated with higher cancer risk. The strongest candi-
date SNP is rs12166475, which alters the binding site for EGR1, 
a transcription factor involved in epithelial-to-mesenchymal 
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transition in EOC (46). The alternative allele of this variant is also 
predicted to increase the binding affinity of WT1, a biomarker 
commonly expressed in HGSOCs. WT1 can have both repressive 
and activating effects on gene expression (47). Additional func-
tional analysis of the possible interaction between rs12166475 
and CHEK2 will be required to validate these findings and to 
elucidate the transcriptional consequences of allele-dependent 
EGR1/WT1 binding at the site of this SNP. The SNP rs9620817, 
which is most significantly associated with HSCB expression, 
is also a strong candidate. This SNP is predicted to alter CEBPB 
and ETS1 transcription factor binding sites (TFBS), although the 
difference in predicted binding affinity between the two SNP 
alleles is much greater for ETS1. Both rs16986509 and rs9620817 
also alter binding sites for BRCA1, which may be of signifi-
cance given that BRCA1-associated pathways are deregulated 
in approximately half of all HGSOCs (48). BRCA1 can function 
as a co-repressor or co-activator, and regulates gene expression 
by interacting with a myriad of different transcription factors, 
including TP53 and CMYC (49).
Although we conditioned our analysis at 22q12.1 on tagging 
variants spanning the CHEK2 gene, five other genes lie within 
a 500-kb region at either side of the most risk associated SNP 
that could be the target of risk-associated variants at this locus. 
However, somatic analysis of ovarian tumors from TCGA sug-
gests that CHEK2 is the most likely target. It is the only gene 
in the region that is differentially expressed in ovarian tumors 
compared to normal fallopian tube tissues, suggesting that it 
may play a role in EOC development. While CHEK2 was overex-
pressed in ovarian tumors compared to normal fallopian tubes, 
in our eQTL analyses reduced CHEK2 expression was associ-
ated with increased cancer risk, which may suggest that over-
expression occurs at later stages of tumorigenesis but lower 
CHEK2 expression is involved in early cancer development. This 
hypothesis is consistent with the moderate risk of breast cancer 
conferred by CHEK2 loss-of-function variants, where large pop-
ulation-based studies report estimated odds ratios for rare pro-
tein-truncating and splice-junction variants on the order of 6.18 
(95% CI: 1.76–21.8) and 8.75 (95% CI: 1.06–72.2) for missense sub-
stitutions (50). Breast and EOC have shared genetic etiology for 
both high and low penetrance susceptibility genes, providing a 
rationale for why germline genetic variants in or around CHEK2 
may be associated with EOC risk. No similar rationale applies for 
other genes in the region but eQTL analyses identified several 
genotype-gene expression associations that indicate alterna-
tive candidate target genes. The strongest association was with 
the XBP1 gene in peripheral lymphocytes, although the most 
significant eQTL SNP for this gene was not predicted to alter a 
TFBS within an active regulatory element in EOC precursor cells. 
We also identified highly statistically significant cis-eQTL asso-
ciations between risk SNPs and expression of both CHEK2 and 
HSCB. However, the true importance of these eQTL associations 
is unclear given that they were identified in tissues that are 
not associated with EOC development. Several previous studies 
have highlighted the importance of tissue-specific gene expres-
sion when evaluating eQTLs, and stressed the need to perform 
eQTL analysis in tissues relevant to disease development (51). 
We did not identify eQTL associations for any of these genes in 
primary EOCs, although these studies were underpowered.
In summary, we provide evidence that common genetic vari-
ants in a region on chromosome 22q12.1 are associated with 
risk of serous ovarian cancer. The most likely target suscepti-
bility gene at this locus is CHEK2 based on a combination of its 
known role in DNA damage response pathways, somatic varia-
tion in gene expression suggesting a role in EOC development, 
and a significant eQTL association with risk-associated vari-
ants. Future studies will be needed to increase the power of 
our genetic association studies by increasing sample size to 
confirm that this region is a true susceptibility locus for ovar-
ian cancer. Finally, detailed functional characterization of this 
locus will be needed to confirm the functional impact of these 
candidate SNPs on their regulatory elements and establish their 
interactions and influence on the target susceptibility gene, as 
has been shown for other common variant susceptibility genes 
and alleles.
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